Paige Mathew, PharmD
Suzetrigine (Journavx, Vertex Pharmaceuticals), a new, nonopioid entry in the treatment armamentarium for moderate to severe acute pain in adults, has garnered considerable attention among clinicians who manage these often challenging patients.
The FDA approved suzetrigine in January as a 50-mg oral tablet. The first-in-class, nonopioid analgesic targets sodium channel pain-signaling pathways in the peripheral nervous system, which prevents pain signals